Overdiagnosis in chest radiographic screening for lung carcinoma : Frequency
β Scribed by David F. Yankelevitz; William J. Kostis; Claudia I. Henschke; Robert T. Heelan; Daniel M. Libby; Mark W. Pasmantier; James P. Smith
- Book ID
- 102106498
- Publisher
- John Wiley and Sons
- Year
- 2003
- Tongue
- English
- Weight
- 66 KB
- Volume
- 97
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
β¦ Synopsis
Abstract
BACKGROUND
The pattern of results in the Mayo Lung Project (MLP), which is the basis for the prevailing recommendations against radiographic screening for lung carcinoma, has led to the assertion that up to 50% of the diagnosed cases of earlyβstage disease in that trial may have represented overdiagnosed, indolent cases. This finding suggests the possibility of such a high frequency of overdiagnosis in chest radiographic lung carcinoma screening in general. In the current study, the authors analyzed data from the MLP and its counterpart study at Memorial SloanβKettering Cancer Center (MSK) to estimate the frequency of overdiagnosis in these studies.
METHODS
For the cases diagnosed as Stage I in the MLP and the MSK studies, the doubling times of tumor volumes were calculated. The calculations were based on size measurements recorded by the original investigators from chest radiographs taken during the course of each study.
RESULTS
The median doubling times were 101 days in the MLP and 144 days in the MSK, times that are somewhat shorter than those reported in published series of adenocarcinoma cases diagnosed outside screening, and only 5% had doubling times exceeding 400 days.
CONCLUSIONS
The hypothesis that earlyβstage lung tumors diagnosed on chest radiography during lung carcinoma screening may frequently be overdiagnosed, indolent cases needs to be rejected. Cancer 2003;97:1271β5. Β© 2003 American Cancer Society.
DOI 10.1002/cncr.11185
π SIMILAR VOLUMES
## Background: In the mayo lung project screening trial, there were more carcinomas identified in the screened group compared with the control group. the screened group had better survival, but there was no difference in lung carcinoma mortality between the screened group and the control group. the